First Capital Advisors Group, Llc. Gilead Sciences, Inc. Transaction History

First Capital Advisors Group, Llc.

$188 Million
Q2 2023

A detailed history of First Capital Advisors Group, Llc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, First Capital Advisors Group, Llc. holds 6,947 shares of GILD stock, worth $463,295. This represents 0.29% of its overall portfolio holdings.

Number of Shares

6,947

Previous 7,067 1.7%

Holding current value

$463,295

Previous $586,000 8.7%

% of portfolio

0.29%

Previous 0.38%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	SELL	$76.01 - $86.7 $9,121 - $10,404	-120 Reduced 1.7%	6,947 $535,000
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $1,700 - $1,937	22 Added 0.31%	7,067 $586,000
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $67,679 - $97,164	-1,086 Reduced 13.36%	7,045 $604,000
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $70,554 - $80,591	1,185 Added 17.06%	8,131 $502,000
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $400,923 - $451,559	6,946 New	6,946 $429,000

Q4 2021 Mar 02, 2022	SELL	$64.88 - $73.64 $515,471 - $585,069	-7,945 Closed	0 $0
Q4 2018 Feb 07, 2019	SELL	$60.54 - $79.0 $80,094 - $104,517	-1,323 Reduced 14.27%	7,945 $497,000
Q3 2018 Oct 24, 2018	BUY	$71.28 - $78.92 $28,369 - $31,410	398 Added 4.49%	9,268 $716,000
Q2 2018 Jul 30, 2018	BUY	$64.88 - $75.68 $74,612 - $87,032	1,150 Added 14.9%	8,870 $628,000
Q1 2018 Apr 11, 2018	SELL	$72.84 - $88.8 $9,979 - $12,165	-137 Reduced 1.74%	7,720 $582,000
Q4 2017 Jan 25, 2018	BUY	$71.15 - $83.52 $46,460 - $54,538	653 Added 9.06%	7,857 $0
Q3 2017 Oct 31, 2017	BUY	$72.11 - $85.47 $519,480 - $615,725	7,204	7,204 $584,000

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $83.6B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Capital Advisors Group, Llc., based on Form 13F filings with the SEC.

News

Stay updated on First Capital Advisors Group, Llc. with notifications on news.

Account

First Capital Advisors Group, Llc. Gilead Sciences, Inc. Transaction History